SCHEMBL4360035

SCHEMBL4360035

COc1cc2nc(/C=C/c3ccccc3)sc2cc1OC

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.59
MEN1 O00255 4/20 0.59
KMT2A Q03164 4/20 0.59
ALDH1A1 P00352 3/20 0.59
HTT P42858 3/20 0.59
KDM4E B2RXH2 2/20 0.59
GAA P10253 2/20 0.59
RAB9A P51151 2/20 0.59
POLB P06746 2/20 0.59
LMNA P02545 2/20 0.57
L3MBTL1 Q9Y468 2/20 0.57
THRB P10828 1/20 0.57
TDP1 Q9NUW8 1/20 0.57
HPGD P15428 1/20 0.55
MAPK1 P28482 1/20 0.55
RECQL P46063 1/20 0.55
PDGFRB P09619 1/20 0.55
PDGFRA P16234 1/20 0.55
CYP1A2 P05177 3/20 0.50
CYP1A1 P04798 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4360036 1.00 MAPT (0.59) MAPTMEN1KMT2AALDH1A1HTT
SCHEMBL4017957 0.82 RAB9A (0.54) MAPTMEN1KMT2AALDH1A1HTT
SCHEMBL4017956 0.82 RAB9A (0.54) MAPTMEN1KMT2AALDH1A1HTT
SCHEMBL22353376 0.80 MAPT (0.51) MAPTMEN1KMT2AALDH1A1HTT
SCHEMBL15949949 0.79 MAPT (0.50) MAPTMEN1KMT2AALDH1A1HTT
SCHEMBL15839282 0.79 MAPT (0.50) MAPTMEN1KMT2AALDH1A1HTT
SCHEMBL2526641 0.78 MAPT (0.74) MAPTMEN1KMT2AALDH1A1HTT
SCHEMBL2526639 0.78 MAPT (0.74) MAPTMEN1KMT2AALDH1A1HTT
SCHEMBL28280854 0.77 MEN1 (0.50) MAPTMEN1KMT2AALDH1A1HTT
SCHEMBL16180704 0.75 MAPT (0.79) MAPTMEN1KMT2AALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009070328-A1 MODULATORS OF THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) PATHWAY FOR USE IN THE TREATMENT OR PREVENTION OF SUBSTANCE ABUSE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2009-06-04 WO disclosed
US-RE36256-E ADMINISTERING ARYL-SUBSTITUTED QUINOXALINE DERIVATIVES AS ANTIPROLIFERATIVE, ANTICARCINOGENIC AND ANTITUMOR AGENTS RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) 1999-07-20 US disclosed
US-5795889-A INHIBITING CELL GROWTH WITH ENZYME INHIBITORS FOR SKIN DISORDERS RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1998-08-18 US disclosed
US-5656643-A QUINOLIN PYRIDINE DERIVATIVES; USEFUL FOR TREATING CANCER, LEKEMIA, PSORIASIS, INFLAMMATORY DISODERS, BONE DISORDERS, ATHEROSCLEROSIS AND RESTENOSIS; CONTROLLS CELLULAR REPRODUCTION RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1997-08-12 US disclosed
US-5646153-A INHIBITING ABNORMAL CELL PROLIFERATION RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1997-07-08 US disclosed
US-5480883-A Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1996-01-02 US disclosed
US-5409930-A Inhibits abnoramal cell proliferation; dimethoxyquinoline/ dimethylquinoline/ quinolineoxide/ and quinoxaline derivatives RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1995-04-25 US disclosed
EP-0584222-A4 BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE RHONE POULENC RORER INT (US) 1994-07-06 EP disclosed
EP-0584222-A1 BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE. RHONE POULENC RORER INT (US) 1994-03-02 EP disclosed
WO-1992020642-A1 BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) 1992-11-26 WO disclosed